{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:04:48Z","timestamp":1769475888626,"version":"3.49.0"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100012670","name":"Dysimmune Diseases Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most frequently observed autoimmune neuropathy in patients with diabetes mellitus (DM). While intravenous immune globulin (IVIG) is a well-established treatment for CIDP, its efficacy in diabetic patients remains uncertain due to their exclusion from prior randomized trials, largely because of concerns about confounding diabetic axonal neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the effectiveness of IVIG therapy in CIDP patients with diabetes mellitus (CIDP-DM) compared to those without diabetes (CIDP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Multi-center, prospective, observational study after at least 3\u2009monthly infusions of IVIG therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Thirty-six patients meeting diagnostic criteria for CIDP were enrolled and stratified into CIDP or CIDP-DM. All patients were followed for a minimum of 3\u2009months after initiating IVIG therapy. Clinical outcomes were assessed at baseline (visit #1) and after 3\u2009monthly IVIG infusions (visit #4) using the adjusted Inflammatory Neuropathy Cause and Treatment Disability Score, the Rasch-built Overall Disability Scale, and the Chronic Acquired Polyneuropathy Patient-reported Index, measured at baseline and at the point of maximal improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>No significant differences were observed in clinical outcomes, treatment-related adverse events, or tolerance between CIDP and CIDP-DM groups, indicating comparable effectiveness of IVIG therapy. However, subgroup analyses revealed that longer duration of diabetes and elevated HbA1c levels were associated with delayed response to IVIG, likely due to cumulative axonal degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite the small number of enrolled patients, IVIG appears equally effective in CIDP patients with and without diabetes. Earlier initiation of IVIG treatment should be considered in CIDP-DM patients to mitigate potential delays in therapeutic response associated with a possibly chronic diabetic neuropathy-related component.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251401496","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:17:18Z","timestamp":1766387838000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy with or without diabetes: insights from a multicenter prospective comparative study"],"prefix":"10.1177","volume":"18","author":[{"given":"Samir P.","family":"Macwan","sequence":"first","affiliation":[{"name":"Eisenhower Health, Rancho Mirage, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Los Angeles Neuromuscular Center, Beverly Hills, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Novak","sequence":"additional","affiliation":[{"name":"Mass General Brigham, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khosro","family":"Farhad","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka","family":"Wong","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Department of Neurology, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Brannagan","sequence":"additional","affiliation":[{"name":"Vagelos College of Physicians and Surgeons, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohail","family":"Masood","sequence":"additional","affiliation":[{"name":"Dysimmune Diseases Foundation, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2507-994X","authenticated-orcid":false,"given":"Fawad","family":"Piracha","sequence":"additional","affiliation":[{"name":"Dysimmune Diseases Foundation, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1134","authenticated-orcid":false,"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[{"name":"Chief Neuromuscular Division, Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.5.751"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.05.007"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.5.758"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181aaea47"},{"key":"e_1_3_4_6_2","first-page":"599","article-title":"CIDP and other inflammatory neuropathies in diabetes\u2014diagnosis and management","volume":"13","author":"Rajabally YA","year":"2017","unstructured":"Rajabally YA, Stettner M, Kieseier BC, et al. CIDP and other inflammatory neuropathies in diabetes\u2014diagnosis and management. Neurology 2017; 13: 599\u2013611.","journal-title":"Neurology"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-322971"},{"issue":"11","key":"e_1_3_4_8_2","first-page":"621","article-title":"Chronic inflammatory polyradiculoneuropathy","volume":"50","author":"Dyck PJ","year":"1975","unstructured":"Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50(11): 621\u2013637.","journal-title":"Mayo Clin Proc"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2169134"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323615"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.1250"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a0fd80"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318208824b"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24985"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03851.x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01167"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01108-4"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.108719"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1088"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251401496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251401496","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251401496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T17:38:25Z","timestamp":1769362705000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251401496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"alternative-id":["10.1177\/17562864251401496"],"URL":"https:\/\/doi.org\/10.1177\/17562864251401496","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251401496"}}